Member Info for euclid55

The ActiPix D100 is the world's first quantitative UV area imaging system. Since its launch, the patented ActiPix technology has been gaining rapid acceptance in a variety of R&D laboratories including proteomics, biocatalysis, biopharma, protein characterisation and formulation optimisation. Its open architecture design makes it ideal as an add-on to many OEM systems.

The miniature detector contains a high resolution 1280x1024 Active Pixel sensor. The entire or selected areas of the imager can be used to enable research scientists to perform current applications with greater flexibility and performance or to develop applications never before possible, e.g. to visualise surface tablet dissolution by UV detection.

https://www.selectscience.net/product-news/challenging-life-science-applications-unlocked-by-uv-area-imaging-detector/?artid=17221

The Paraytec ActiPix D100 UV imaging detector is now available for purchase. This keenly awaited product is set to transform UV-Vis detection technology with its increased sensitivity, minute sample requirements and wide dynamic range - unlocking completely new applications for UV-Vis absorbance detection

The Paraytec ActiPix D100 is a miniature capillary UV detector, designed for on-line monitoring at a single UV wavelength, particularly for use with the separation methods of liquid chromatography and capillary electrophoresis.

Light is delivered via a fibre optic coupled light source. Readout of signals on the active pixel sensor and absorbance calculations are carried out at MHz rates, with all processing done in hardware on custom electronic assemblies. Processed data is output in real-time to computer using an industry-standard high-speed serial data link

Patented signal referencing technology
- Highly sensitive
- Quantitate peptide at 100 pg per µL at 190 nm

Over five orders of magnitude linear dynamic range
- 5 µAU – 0.5 AU
- Reduces the need for dilution
- Enables minor components and major components to be quantified simultaneously

High spatial resolution
- Can resolve peaks in complex mixtures, e.g. proteomics and µUPLC

Real time monitoring of velocity
- Enables integration with process control, e.g. high throughput fraction collection

https://www.selectscience.net/products/actipix-d100-uv-area-imaging-system/?prodID=14184#tab-2

Hello GLT19990, re your question below - from what I understand this test is targeting high sensitivity, so it will find (If testing proves all ok) low viral loads in asymptomatic people. That is one unique point about this 5 min Covid test.

" but what if the viral load is very small and the person is positive but not infectious, can our test potentially be used to find INFECTIOUS and not just positives"

P2F has received a conditional order for 1 million face masks per month for a period of one year from 1 January 2021. This order is subject to contract and conditional on the masks successfully completing antiviral and other performance tests and receiving the necessary PPE certifications. The order is also conditional on the buyer entering into sales contracts to sell a similar volume of masks per month.

If they manage to comp;ete the 2nd part of the PoC test next Friday, they then may

20,000 ozs x $2k = / 1.29 Gbp fx rate = approx £31m gross value excluding costs

Don't forget if we go higher we have the 1.6m warrants at 40p strike price - Will be another £640,000 cash into the BRH cash account ( 1.6m x 40p strike price)

https://www.investegate.co.uk/braveheart-inv-group--brh-/rns/further-placing-to-raise--350-000/202005010700055793L/

TomV, don't jump to the conclusion they will complete the test in 90 seconds please.

It will take longer than thProfessor was showing yesterday, although the initial result came in 90 seconds, it may not get to that when it goes via the c& signal generation device - Thats where it may take the up to 5 mints

So p;ease don't make the conclusion this is now a 90 secs results device.

Until it's fully confirmed to us by BRH / Sheffield University, best not to jump to conclusions here

Thanks

https://twitter.com/carlsmythe/status/1313056511988465664

about 700,000 since 29 Sept to date

seen 5 x 100k block sells in the past few days - someone losing interest or worrying the poo is droping

Marc Lipsitch
@mlipsitch
·
8h
concerns that the approach fails to optimize less practically important objectives (eg probability per case of a negative test when someone is or will become infectious, regardless of how fast that false neg is corrected by another test), in a world without constraints.
Marc Lipsitch
@mlipsitch
·
8h
I think decision making should be based on optimizing important objectives given constraints (and of course also removing those constraints, but that is a longer game and will be easier to do if we control the virus short term).
Carl “DownloadNHSTrack&Trace” Smythe
@carlsmythe
·
8h
Or we COULD aim for a fast AND sensitive test. How cool would that be?
Kevin Stewart
@stewak2
·
7h
It needs to be inexpensive as well, so that it can be frequent
Carl “DownloadNHSTrack&Trace” Smythe
@carlsmythe
Replying to
@stewak2

@mlipsitch
and 9 others
Exactly. That’s not impossible.

#fiveminutetest

https://twitter.com/carlsmythe/status/1311441581237563392

Https://twitter.com/carlsmythe/status/1311441581237563392

what is the up front capital costings to set up the plant?

Good spot:

"However, there is no certified manufacturing of face masks in the UK However, there is no certified manufacturing of face masks in the UK "

Https://gtr.ukri.org/projects?ref=63429

Pharm2Farm (Lead) and Flexotronix (subcontractor) aim to combine their leading nanotechnology capabilities to produce a highly enhanced anti-viral face mask to meet N95/FFP2 and FFP3 specifications.
_ _ _________________________________________________________________
FFP3 masks have to pass tests set out in a European standard (European EN149:2001 – for “disposable particulate respirators” and you’ll see that code printed on the mask itself). The masks can be made by different manufacturers and won’t all have the same specifications, but they will all have to meet those minimum standards.

Wearing an FFP3 mask, you’ll be protected from inhaling solid particles, non-volatile liquid particles and oil-based mists. FFP3 face masks are the standard that the NHS demands for its staff. The level of protection is greater than that offered by FFP1 or FFP2 masks.

N95 masks – US standard:

N95 face masks must meet US standards. However (and as you might expect), N99 and N100 face masks offer a greater level of protection than N95 masks in terms of the proportion of tiny particles that are filtered out. In fact, when considering filtration requirements, N99 masks are a closer equivalent to FFP3 masks, while N95 masks are a closer equivalent to FFP2 masks.

Https://www.finder.com/uk/n95-vs-ffp3-face-masks

A survey conducted by the British Medical Association found that half of doctors working in high risk environments do not have access to appropriate face masks. Also, the British Dental Association has lamented the typical UK dentist who can go through 250 face masks per week is now restricted to 100 no matter the practice size.

A study by HSE and PHE on the use of PPE in health care settings published on the 27th of March recommended the use of FFP3 but if not available FFP2 and N95 masks can be used. However, there is no certified manufacturing of face masks in the UK and there is only one manufacturer of spunbond and meltblown nonwoven medical fabrics, a material used for FFP2/N95 disposable respirators.

Pharm2Farm (Lead) and Flexotronix (subcontractor) aim to combine their leading nanotechnology capabilities to produce a highly enhanced anti-viral face mask to meet N95/FFP2 and FFP3 specifications.

Https://gtr.ukri.org/projects?ref=63429

coud of been a sell, which is why we are down to 13p on the bid price

https://gb.wallmine.com/tsx/inv/officer/1896189/robert-pollock

Robert Pollock is Independent Director of INV Metals Inc. Chief Executive Officer and director of Primary Capital Inc., exempt market dealer (2008 to present) Director of Merus Labs International Inc., (amalgamation of Merus Labs International Inc. and Envoy Capital Group Inc.), specialty pharmaceutical company (2011 to present) President and Chief Executive Officer of Envoy Capital Group Inc.,

Yes correct, very good spot: so again imagine what they will do with a succesfull 5 min test like our's - if it proves all good - instant results there & then in 5 mins....................If they bought £160m of these, imagine they could place a similar amount or more with ours!

The test uses the gold-standard PCR technology but does not need a lab. A nurse or doctor takes a nose swab from a patient and inserts it into a small single-use cartridge. That goes into the “NudgeBox” which processes the sample in 90 minutes, but it can only take one sample at a time. That means each box can only process a maximum of 16 tests in 24 hours. One hospital using it currently has 20 boxes.

https://www.theguardian.com/world/2020/sep/17/new-uk-covid-test-is-effective-but-wont-impact-numbers-as-hoped